BCL2 and leukemia: Importantly, this increased high metabolic activity in VEN-resistant cells can serve as a target for therapeutic intervention and co-targeting of BCL-2 and OxPhos showed synergistic anti-leukemia activity, thus providing a basis for further preclinical and potential clinical evaluation.